Raymond Brandicourt Olivier's Insider Trades & SAST Disclosures
Raymond Brandicourt Olivier's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 1,558 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 8, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Raymond Brandicourt Olivier.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| Vaxcyte Inc | Raymond Brandicourt Olivier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 40,113 | 40,113 | - | - | Stock Option (right to buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 34,151 | 34,151 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 16,341 | 16,341 (0%) | 0% | 0 | Ordinary Shares | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 27,794 | 27,794 | - | - | Share Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges